Traganos F, Evenson D P, Staiano-Coico L, Darzynkiewicz Z, Melamed M R
Cancer Res. 1980 Mar;40(3):671-81.
Dihydroxyanthraquinone, 1,4-dihydroxy-5,8-bis(( (2-[(2-hydroxyethyl)amino]ethyl)amino))-9,10-anthracenedione (NSC 279836), was observed to alter the cell cycle kinetics of a variety of mammalian cell lines as monitored by flow cytometry. Continuous exposure of Friend leukemia, L1210, and Chinese hamster cells to the drug in vitro at concentrations of 1.0 to 10 ng/ml resulted in the accumulation of cells in G2 by 24 hr in culture. When cells were exposed to dihydroxyanthraquinone for 30 min, washed free of drug, and cultured in fresh medium for 24 hr, a 10 times higher drug concentration was required to produce a G2 block identical to that observed during continuous exposure. Stimulation of human lymphocytes by phytohemagglutinin could be inhibited in a dose-dependent manner by brief pretreatment of cells with the drug. However, while previously stimulated but as yet noncycling lymphocytes were profoundly affected by much lower concentrations, proliferating lymphocytes were refractory to treatment with the drug up to a concentration of 1 microgram/ml. Exposure to the drug for 24 hr, at concentrations as low as 3.2 ng/ml, inhibited colony formation of exponentially growing Chinese hamster cells by 50%, whereas stationary culture required an 8-fold higher concentration to produce the same results. Drug concentrations in the range of 0.3 to 0.8 micrograms/ml over a period of 24 hr reduced the viability of Friend leukemia and L1210 cells by 50% as measured by trypan blue dye exclusion. In contrast, human lymphocyte viability was only mildly affected following 24 hr incubation with up to 5.0 micrograms dihydroxyanthraquinone per ml. There was a marked effect on cellular RNA content in two of the cell lines tested. Friend leukemia and L1210 cells blocked in G2 by the drug manifested a 140 and 70% increase in RNA content, respectively, when compared to control cells. In addition, though suboptimal concentrations of the drug resulted in a transient accumulation of cells in G2, optimal drug concentrations not only blocked cells in G2 but in the case of Friend leukemia and L1210 cells led to an increase in the proportion of cells with greater than 4C amounts of DNA. The results obtained with dihydroxyanthraquinone were compared to those obtained previously with a nonhydroxylated analog, anthracenedione (NCS 287513).
二羟基蒽醌,1,4 - 二羟基 - 5,8 - 双(((2 - [(2 - 羟乙基)氨基]乙基)氨基)) - 9,10 - 蒽二酮(NSC 279836),经流式细胞术监测发现,它能改变多种哺乳动物细胞系的细胞周期动力学。将弗氏白血病细胞、L1210细胞和中国仓鼠细胞在体外以1.0至10纳克/毫升的浓度持续暴露于该药物24小时,会导致细胞在G2期积累。当细胞暴露于二羟基蒽醌30分钟,洗去药物,然后在新鲜培养基中培养24小时时,需要高出10倍的药物浓度才能产生与持续暴露时相同的G2期阻滞。用该药物对细胞进行短暂预处理,可剂量依赖性地抑制植物血凝素对人淋巴细胞的刺激。然而,虽然先前受到刺激但尚未进入细胞周期的淋巴细胞受到低得多浓度药物的深刻影响,但增殖的淋巴细胞对高达1微克/毫升浓度的药物治疗具有抗性。在低至3.2纳克/毫升的浓度下暴露于该药物24小时,可使指数生长的中国仓鼠细胞的集落形成抑制达50%,而静止培养的细胞则需要高出8倍的浓度才能产生相同结果。在24小时内,0.3至0.8微克/毫升范围内的药物浓度可使弗氏白血病细胞和L1210细胞的活力通过台盼蓝拒染法测定降低50%。相比之下,每毫升高达5.0微克二羟基蒽醌孵育24小时后,人淋巴细胞活力仅受到轻微影响。在所测试的两种细胞系中,该药物对细胞RNA含量有显著影响。与对照细胞相比,因该药物阻滞在G2期的弗氏白血病细胞和L1210细胞的RNA含量分别增加了140%和70%。此外,虽然次优浓度的药物会导致细胞在G2期短暂积累,但最佳药物浓度不仅会使细胞阻滞在G2期,而且对于弗氏白血病细胞和L1210细胞而言,还会导致DNA含量大于4C的细胞比例增加。将二羟基蒽醌得到的结果与先前用非羟基化类似物蒽二酮(NCS 287513)得到的结果进行了比较。